# Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

> **NCT02520518** · PHASE2 · TERMINATED · sponsor: **Christopher Bell** · enrollment: 9 (actual)

## Conditions studied

- Weight Loss

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo
- **BEHAVIORAL:** Weight maintenance
- **BEHAVIORAL:** Ad libitum dietary intake
- **BEHAVIORAL:** Dietary restriction

## Key facts

- **NCT ID:** NCT02520518
- **Lead sponsor:** Christopher Bell
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Designed a new modified/simplified protocol see NCT 03180489
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520518, "Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02520518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*